Key result
First-line medication treatment for hypertension in competitive athletes should include ACE inhibitors, angiotensin II receptor blockers, and calcium channel blockers.
In competitive athletes, first-line antihypertensive therapy should include ACE inhibitors, ARBs, and CCBs, with sports participation limited in severe or complicated cases.
May support ACEi/ARBs/CCBs as first-line in hypertensive athletes; leaves open confirmation in randomized trials.
Hypertension is the most common cardiovascular disease in athletes. It is an important cause of long-term morbidity and mortality, even in a fit, athletic population. Management options to reduce these long-term risks exist that have minimal impact on athletic performance. Identification and management of underlying lifestyle factors and diseases that may lead to secondary hypertension is critical. These include substance abuse, medications, and underlying medical conditions. After evaluation and management of these issues, medications can be used to reduce blood pressure. In the athletic population, first-line medication treatment should include ACE inhibitors, angiotensin II receptor blockers (ARB), and calcium channel blockers (CCB). The response to treatment should be followed closely to ensure adequate blood pressure control. Athletic participation in sports with high dynamic load should be limited in individuals with stage 2 hypertension or stage 1 hypertension with evidence of end organ damage.
No takes yet. Share an insight, caveat, or question.
Henry F. Pelto (2017) conducted a review in Hypertension in competitive athletes. Hypertensive Medications (ACE inhibitors, ARBs, CCBs) was evaluated. First-line medication treatment for hypertension in competitive athletes should include ACE inhibitors, angiotensin II receptor blockers, and calcium channel blockers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: